Zeta Ubiquitin Antibody. Zeta’s recombinant mouse antibody recognizes ubiquitin, a highly conserved and plays an essential role in the ubiquitin-proteasome pathway. In ubiquitination process, the process is first activated by forming a thiol-ester complex with the activation component E1, which is then transferred to ubiquitin-carrier protein E2, followed by to ubiquitin ligase E3 for final delivery to epsilon-NH2 of the target protein lysine residue. IkB, p53, cdc25A, Bcl-2 etc. are shown as targets of ubiquitin-proteasome process as part of regulation of cell cycle progression, differentiation, cell stress response, and apoptosis. Moreover, Ubiquitin have been reported to bind covalently with pathological inclusions which are resistant to degradation including neurofibrillary tangles and paired helical filaments in Alzheimer’s disease, Lewy bodies seen in Parkinson’s disease, and Pick bodies found in Pick’s disease.
Zeta Corporation is a leader in recombinant monoclonal IVD antibodies for immunohistochemistry (IHC) offering 400+ tumor and tissue specific relevant products developed by a pathologist for pathologists. Visit Precision Recombinant Antibodies – IVD Antibodies – About Zeta Corporation (zeta-corp.com) to learn more about Zeta Corporation.